ReviewJournal of neural transmission (Vienna, Austria : 1996)2017
Classification of advanced stages of Parkinson's disease: translation into stratified treatments.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Long-term effect of the German Parkinson's disease multimodal complex treatment: a clinical trial with randomized allocation.BMC neurology · 2026Trial
- Article
- Article
- The German Parkinson expert meetings.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Effect of Structured Exercise for the Rehabilitation of Patients With Chronic Parkinson's Disease.Cureus · 2026Article
- Article
- Longitudinal Study of Treatment Variability for Parkinson's Disease across Specialized Centers.Movement disorders clinical practice · 2025Article
- Morphological profiling reveals neuroprotection via mitochondrial uncoupling in human dopaminergic neurons.Scientific reports · 2025Article
- Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Review
- Exploring the Role of Reactive Oxygen Species in the Pathogenesis and Pathophysiology of Alzheimer's and Parkinson's Disease and the Efficacy of Antioxidant Treatment.Antioxidants (Basel, Switzerland) · 2024Review
- Vision-based gait analysis for real-time Parkinson disease identification and diagnosis system.Health systems (Basingstoke, England) · 2024Article
- Functional neural networks stratify Parkinson's disease patients across the spectrum of cognitive impairment.Brain and behavior · 2024Article
- A single centre prospective study of three device-assisted therapies for Parkinson's disease.NPJ Parkinson's disease · 2023Article
- The heterogeneity of Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Prediction of Cognitive Decline in Parkinson's Disease Using Clinical and DAT SPECT Imaging Features, and Hybrid Machine Learning Systems.Diagnostics (Basel, Switzerland) · 2023Article
- Effectiveness and Therapeutic Mechanism of Pharmacopuncture for Pain in Parkinson's Disease: A Study Protocol for a Pilot Pragmatic Randomized, Assessor-Blinded, Usual Care-Controlled, Three-Arm Parallel Trial.International journal of environmental research and public health · 2023Article
- Parkinson's disease progression: Increasing expression of an invariant common core subnetwork.NeuroImage. Clinical · 2023Article
- Vagal cross-sectional area correlates with parasympathetic dysfunction in Parkinson's disease.Brain communications · 2023Article
- Cognitive Function and Postural Control Strategies in Relation to Disease Progression in Patients with Parkinson's Disease.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced stages of Parkinson's disease (advPD) still impose a challenge in terms of classification and related stage-adapted treatment recommendations. Previous concepts that define advPD by certain milestones of motor disability apparently fall short in addressing the increasingly recognized complexity of motor and non-motor symptoms and do not allow to account for the clinical heterogeneity that require more personalized approaches. Therefore, deep phenotyping approaches are required to characterize the broad-scaled, continuous and multidimensional spectrum of disease-related motor and non-motor symptoms and their progression under real-life conditions. This will also facilitate the reasoning for clinical care and therapeutic decisions, as neurologists currently have to refer to clinical trials that provide guidance on a group level; however, this does not always account for the individual needs of patients. Here, we provide an overview on different classifications for advPD that translate into critical phenotypic patterns requiring the differential therapeutic adjustments. New concepts refer to precision medicine approaches also in PD and first studies on genetic stratification for therapeutic outcomes provide a potential for more objective treatment recommendations. We define novel treatment targets that align with this concept and make use of emerging device-based assessments of real-life information on PD symptoms. As these approaches require empowerment of patients and integration into treatment decisions, we present communication strategies and decision support based on new technologies to adjust treatment of advPD according to patient demands and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.